Novo Nordisk settles securities lawsuit in Denmark

A lawsuit concerning alleged market manipulation on the US insulin market has come to a settlement between plaintiffs, shareholders in Novo Nordisk, and the company.

Photo: Niels Hougaard/ERH

Danish pharmaceutical firm Novo Nordisk has settled a 2019 lawsuit concerning an allegation that shareholders had been misled about insulin sales in the US, the company announces in a press release.

According to the statement, the settlement contains no admission of wrongdoing, and no payment to the plaintiffs will be made by Novo Nordisk.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs